Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | PPM1G | O15355 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | PPM1A | P35813 | 1/20 | 0.37 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754326 | 0.93 | PTPN1 (0.38) | PDE1BPTPN1CCR2ALDH1A1HTT | |
| SCHEMBL18161034 | 0.92 | PDE1B (0.41) | PDE1BPTPN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24263381 | 0.91 | PDE1B (0.39) | PDE1BPTPN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL16812352 | 0.89 | PDE1B (0.38) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16794693 | 0.88 | MAPT (0.42) | PDE1BALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL16812493 | 0.88 | NR3C1 (0.39) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16812355 | 0.88 | ALDH1A1 (0.39) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16812486 | 0.87 | NPC1 (0.40) | PDE1BALDH1A1SMN1; SMN2NR3C1MEN1 | |
| SCHEMBL16812482 | 0.87 | NPC1 (0.40) | PDE1BALDH1A1SMN1; SMN2NR3C1MEN1 | |
| SCHEMBL3017547 | 0.86 | BCL2A1 (0.40) | PDE1BCCR2SMN1; SMN2NR3C1TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4692096-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| WO-2024199479-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4281458-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | Anrui Biomedical Technology (Guangzhou) Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-117043164-A | Imidazopyridazine or pyrazolopyrimidine compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023155900-A1 | FIVE-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND, AND USE THEREOF AS PROTEIN KINASE INHIBITOR | 上海轶诺药业有限公司 | 2023-08-24 | — | — | WO | disclosed |
| EP-3377496-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2018-09-26 | — | — | EP | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018067432-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018067432-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080131-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | PDE1B 3074/4885PTPN1 541/4885CCR2 796/4885 |
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | TYK2, PTK2B, JAK1 | PDE1B 918/4885PTPN1 178/4885CCR2 949/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | PDE1B 3438/4885PTPN1 474/4885CCR2 2810/4885 |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | PDE1B 1789/4885PTPN1 780/4885CCR2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.